Jay C. Fournier

Jay C. Fournier

Auto-generated profile, based on publicly available information

Jay C. Fournier

Department of Psychiatry and Behavioral Health, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2010 in JAMA
Verified
Journal Article
Closed access
PDF file
JFJay C. Fournier
Jay C. Fournier
RDRobert J. DeRubeis
Robert J. DeRubeis
SHSteven D. Hollon
Steven D. Hollon
SDSona Dimidjian
Sona Dimidjian
JAJay D. Amsterdam
Jay D. Amsterdam
JFJan Fawcett
Jan Fawcett
ContextAntidepressant medications represent the best established treatment for major depressive disorder, but there is little evidence that they have a specific pharmacological effect relative to pill placebo for patients with less severe depression.ObjectiveTo estimate the relative benefit of medication vs placebo across a wide range of initial symptom severity in patients diagnosed with depression.Data SourcesPubMed, PsycINFO, and the Cochrane Library databases were searched from January 1980 through March 2009, along with references from meta-analyses and reviews.Study SelectionRandomized placebo-controlled trials of antidepressants approved by the Food and Drug Administration in the treatment of major or minor depressive disorder were selected. Studies were included if their authors provided the requisite original data, they comprised adult outpatients, they included a medication vs placebo comparison for at least 6 weeks, they did not exclude patients on the basis of a placebo washout period, and they used the Hamilton Depression Rating Scale (HDRS). Data from 6 studies (718 patients) were included.Data ExtractionIndividual patient-level data were obtained from study authors.ResultsMedication vs placebo differences varied substantially as a function of baseline severity. Among patients with HDRS scores below 23, Cohen d effect sizes for the difference between medication and placebo were estimated to be less than 0.20 (a standard definition of a small effect). Estimates of the magnitude of the superiority of medication over placebo increased with increases in baseline depression severity and crossed the threshold defined by the National Institute for Clinical Excellence for a clinically significant difference at a baseline HDRS score of 25.ConclusionsThe magnitude of benefit of antidepressant medication compared with placebo increases with severity of depression symptoms and may be minimal or nonexistent, on average, in patients with mild or moderate symptoms. For patients with very severe depression, the benefit of medications over placebo is substantial.

8 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RDRobert J. DeRubeis
Robert J. DeRubeis
ZCZachary D Cohen
Zachary D Cohen
NFNicholas R. Forand
Nicholas R. Forand
JFJay C. Fournier
Jay C. Fournier
LGLois A. Gelfand
Lois A. Gelfand
LLLorenzo Lorenzo-Luaces
Lorenzo Lorenzo-Luaces
Advances in personalized medicine require the identification of variables that predict differential response to treatments as well as the development and refinement of methods to transform predictive information into actionable recommendations. To illustrate and test a new method for integrating predictive information to aid in treatment selection, using data from a randomized treatment comparison. Data from a trial of antidepressant medications (N = 104) versus cognitive behavioral therapy (N = 50) for Major Depressive Disorder were used to produce predictions of post-treatment scores on the Hamilton Rating Scale for Depression (HRSD) in each of the two treatments for each of the 154 patients. The patient's own data were not used in the models that yielded these predictions. Five pre-randomization variables that predicted differential response (marital status, employment status, life events, comorbid personality disorder, and prior medication trials) were included in regression models, permitting the calculation of each patient's Personalized Advantage Index (PAI), in HRSD units. For 60% of the sample a clinically meaningful advantage (PAI≥3) was predicted for one of the treatments, relative to the other. When these patients were divided into those randomly assigned to their “Optimal” treatment versus those assigned to their “Non-optimal” treatment, outcomes in the former group were superior (d = 0.58, 95% CI .17—1.01). This approach to treatment selection, implemented in the context of two equally effective treatments, yielded effects that, if obtained prospectively, would rival those routinely observed in comparisons of active versus control treatments.

1 January 2009 in Journal of Consulting and Clinical Psychology
Verified
Journal Article
Closed access
JFJay C. Fournier
Jay C. Fournier
RDRobert J. DeRubeis
Robert J. DeRubeis
RSRichard C. Shelton
Richard C. Shelton
SHSteven D. Hollon
Steven D. Hollon
JAJay D. Amsterdam
Jay D. Amsterdam
RGRobert Gallop
Robert Gallop
A recent randomized controlled trial found nearly equivalent response rates for antidepressant medications and cognitive therapy in a sample of moderate to severely depressed outpatients. In this article, the authors seek to identify the variables that were associated with response across both treatments as well as variables that predicted superior response in one treatment over the other. The sample consisted of 180 depressed outpatients: 60 of whom were randomly assigned to cognitive therapy; 120 were assigned to antidepressant medications. Treatment was provided for 16 weeks. Chronic depression, older age, and lower intelligence each predicted relatively poor response across both treatments. Three prescriptive variables-marriage, unemployment, and having experienced a greater number of recent life events-were identified, and each predicted superior response to cognitive therapy relative to antidepressant medications. Thus, 6 markers of treatment outcome were identified, each of which might be expected to carry considerable clinical utility. The 3 prognostic variables identify subgroups that might benefit from alternative treatment strategies; the 3 prescriptive variables identify groups who appear to respond particularly well to cognitive therapy.

29 January 2013 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
AVA Versace
A Versace
AAA C Andreazza
A C Andreazza
LYL T Young
L T Young
JFJ C Fournier
J C Fournier
JAJ R C Almeida
J R C Almeida
MPM L Phillips
M L Phillips
Diffusion tensor imaging (DTI) studies consistently reported abnormalities in fractional anisotropy (FA) and radial diffusivity (RD), measures of the integrity of white matter (WM), in bipolar disorder (BD), that may reflect underlying pathophysiologic processes. There is, however, a pressing need to identify peripheral measures that are related to these WM measures, to help identify easily obtainable peripheral biomarkers of BD. Given the high lipid content of axonal membranes and myelin sheaths, and that elevated serum levels of lipid peroxidation are reported in BD, these serum measures may be promising peripheral biomarkers of underlying WM abnormalities in BD. We used DTI and probabilistic tractography to compare FA and RD in ten prefrontal-centered WM tracts, 8 of which are consistently shown to have abnormal FA (and/or RD) in BD, and also examined serum lipid peroxidation (lipid hydroperoxides, LPH and 4-hydroxy-2-nonenal, 4-HNE), in 24 currently euthymic BD adults (BDE) and 19 age- and gender-matched healthy adults (CONT). There was a significant effect of group upon FA in these a priori WM tracts (BDECONT: F[1,41]=10.3; P=0.003), and a significant between-group difference in LPH (BDE>CONT: t[40]=2.4; P=0.022), but not in 4-HNE. Multivariate multiple regression analyses revealed that LPH variance explained, respectively, 59 and 51% of the variance of FA and RD across all study participants. This is the first study to examine relationships between measures of WM integrity and peripheral measures of lipid peroxidation. Our findings suggest that serum LPH may be useful in the development of a clinically relevant, yet easily obtainable and inexpensive, peripheral biomarkers of BD.

21 April 2020 in Psychological Medicine
Verified
Journal Article
Closed access
PDF file
SSShannon Sauer-Zavala
Shannon Sauer-Zavala
JFJay C. Fournier
Jay C. Fournier
SSStephanie Jarvi Steele
Stephanie Jarvi Steele
BWBrittany K. Woods
Brittany K. Woods
MWMengxing Wang
Mengxing Wang
DBDavid H. Barlow
David H. Barlow
Background: Neuroticism is associated with the onset and maintenance of a number of mental health conditions, as well as a number of deleterious outcomes (e.g. physical health problems, higher divorce rates, lost productivity, and increased treatment seeking); thus, the consideration of whether this trait can be addressed in treatment is warranted. To date, outcome research has yielded mixed results regarding neuroticism's responsiveness to treatment, perhaps due to the fact that study interventions are typically designed to target disorder symptoms rather than neuroticism itself. The purpose of the current study was to explore whether a course of treatment with the unified protocol (UP), a transdiagnostic intervention that was explicitly developed to target neuroticism, results in greater reductions in neuroticism compared to gold-standard, symptom focused cognitive behavioral therapy (CBT) protocols and a waitlist (WL) control condition.Method: Patients with principal anxiety disorders (N = 223) were included in this study. They completed a validated self-report measure of neuroticism, as well as clinician-rated measures of psychological symptoms.Results: At week 16, participants in the UP condition exhibited significantly lower levels of neuroticism than participants in the symptom-focused CBT (t(218) = −2.17, p = 0.03, d = −0.32) and WL conditions(t(207) = −2.33, p = 0.02, d = −0.43), and these group differences remained after controlling for simultaneous fluctuations in depression and anxiety symptoms.Conclusions: Treatment effects on neuroticism may be most robust when this trait is explicitly targeted.

1 February 2008 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
JFJay C. Fournier
Jay C. Fournier
RDRobert J. DeRubeis
Robert J. DeRubeis
RSRichard C. Shelton
Richard C. Shelton
RGRobert Gallop
Robert Gallop
JAJay D. Amsterdam
Jay D. Amsterdam
SHSteven D. Hollon
Steven D. Hollon
Background: There is conflicting evidence about comorbid personality pathology in depression treatments.Aims: To test the effects of antidepressant drugs and cognitive therapy in people with depression distinguished by the presence or absence of personality disorder.Method: Random assignment of 180 out-patients with depression to 16 weeks of antidepressant medication or cognitive therapy. Random assignment of medication responders to continued medication or placebo, and comparison with cognitive therapy responders over a 12-month period.Results: Personality disorder status led to differential response at 16 weeks; 66%v.44% (antidepressantsv.cognitive therapy respectively) for people with personality disorder, and 49%v.70% (antidepressantsv.cognitive therapy respectively) for people without personality disorder. For people with personality disorder, sustained response rates over the 12-month follow-up were nearly identical (38%) in the prior cognitive therapy and continuation-medication treatment arms. People with personality disorder withdrawn from medication evidenced the lowest sustained response rate (6%). Despite the poor response of people with personality disorder to cognitive therapy, nearly all those who did respond sustained their response.Conclusions: Comorbid personality disorder was associated with differential initial response rates and sustained response rates for two well-validated treatments for depression.